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Continuous spikes and waves during sleep (CSWS) is an epileptic encephalopathy characterized in most patients by (1) difficult
to control seizures, (2) interictal epileptiform activity that becomes prominent during sleep leading to an electroencephalogram
(EEG) pattern of electrical status epilepticus in sleep (ESES), and (3) neurocognitive regression. In this paper, we will summarize
current epidemiological, clinical, and EEG knowledge on CSWS and will provide suggestions for treatment. CSWS typically
presents with seizures around 2–4 years of age. Neurocognitive regression occurs around 5-6 years of age, and it is accompanied
by subacute worsening of EEG abnormalities and seizures. At approximately 6–9 years of age, there is a gradual resolution of
seizures and EEG abnormalities, but the neurocognitive deficits persist in most patients. The cause of CSWS is unknown, but
early developmental lesions play a major role in approximately half of the patients, and genetic associations have recently been
described.High-dosebenzodiazepinesandcorticosteroidshavebeensuccessfullyusedtotreatclinicalandelectroencephalographic
features.Corticosteroidsareoftenreservedforrefractorydiseasebecauseofadverseevents.Valproate,ethosuximide,levetiracetam,
sulthiame, and lamotrigine have been also used with some success. Epilepsy surgery may be considered in a few selected patients.
1. Introduction
Continuous spikes and waves during sleep (CSWS) is an
epileptic encephalopathy, that is, a condition in which the
epileptic processes themselves are thought to contribute to
the disturbance in cerebral function. CSWS is characterized
by (1) seizures, (2) neurocognitive regression, and (3) an
electroencephalography (EEG) pattern of electrical status
epilepticus during sleep (ESES) [1–6]. ESES is characterized
by marked sleep potentiation of epileptiform activity in the
transition from wakefulness to sleep that leads to near-
continuous bilateral (or occasionally lateralized) slow spikes
and waves that occupy a significant proportion of nonrapid
eye movement (non-REM) sleep [2, 4].
Inthisreview,wesummarizeepidemiological,etiological,
clinical, and EEG features in CSWS based on available data.
We also suggest an approach to manage this syndrome and
present it in the framework of a more general childhood
seizure susceptibility syndrome.
2. Definitions
Theterms“ESES,”“CSWS,”and“Landau-Kleffnersyndrome”
have been used interchangeably in the literature to refer to
the EEG pattern of frequent spike-waves or to the associated
epilepticencephalopathywithregression[6–8].TheEEGpat-
ternandtheassociatedepilepticencephalopathyaredifferent
concepts that might require differentiated names. A recent
survey in North-America showed that the use of concepts
in ESES and CSWS is very heterogeneous, and a common
terminology is not available [9]. For the purposes of this
review ,wewilluse“ESES”whenreferringtotheEEGpattern,
“CSWS” when referring to the epileptic encephalopathy with2 Epilepsy Research and Treatment
global regression, and “Landau-Kleffner syndrome” (LKS)
when referring to the epileptic encephalopathy with mainly
language regression. We use this terminology in order to
give unequivocal names to the different concepts, but we
acknowledge that terminology is in progress, and it may
change in the future.
The main focus of this review is on CSWS, a severe
epileptic encephalopathy with (1) ESES on EEG, (2) seizures,
and (3) developmental regression in, at least, two domains of
development. Therefore, patients with developmental regres-
sion in mainly the language domain will be reviewed under
the associated condition of “Landau-Kleffner syndrome” [4].
The borders between these entities are often difficult to
delineate, and conditions may be considered as different
presentations of the same electroclinical spectrum [10].
3. Epidemiology
CSWS is a rare condition that occurs only in children and
adolescents. In an outpatient pediatric series, 1 out of 440
(0.2%) epileptic children had CSWS [11]. In tertiary pediatric
epilepsy centers, around 0.5%–0.6% of patients were diag-
nosed with CSWS [12, 13]. Among children and adolescents
undergoing epilepsy surgery for intractable seizures, about
1-2% of patients presented with CSWS [14, 15]. The exact
frequency of CSWS is difficult to assess because of incon-
sistent inclusion criteria and study methodologies. Gender
distribution in large series and reviews shows a male-to-
femaleratioof4:3to3:2[2, 16–21].
4. Clinical Features
CSWSisanage-relatedepilepticencephalopathyinwhichthe
clinical features evolve over time. The evolving nature of this
syndromeallowstherecognitionofseveralclinicalevents:age
at seizure onset, age at neurocognitive regression, and age at
seizure freedom. These clinical events provide information
to identify electroclinical stages in CSWS, namely, dormant
stage (from birth to epilepsy onset), prodromal stage (from
epilepsy onset to regression), acute stage (from regression to
seizure freedom), and residual stage (after seizure freedom)
[22–24].
4.1. Seizures. A typical child with CSWS initially has normal
or moderately abnormal baseline development and then
presents with seizures around 2–4 years of age. Patients with
s t r u c t u r a ll e s i o n so ft h eb r a i nt e n dt oh a v es e i z u r e se a r l i e r
(around 2 years of age) than patients without lesions (around
4yearso fage)[4].Seizuresduringtheprodromalstageoccur
typicallyoutofsleepandarefrequentlyclonicortonic-clonic
unilateral seizures that rarely progress to unilateral status
epilepticus [6, 16, 25]. During the prodromal stage, two or
m o r es e i z u r et y p e sa r es e e ni no n l y2 0 %o fp a t i e n t s[ 16].
During the acute stage, there is a marked increase in the
frequencyandtypesofseizures,whichbecomemoredifficult
to control [2, 6, 16, 25, 26]. Unilateral seizures become rare,
while atonic seizures appear and the motor components of
the seizures lead to sudden falls. Atypical absence seizures
increase in frequency and severity and may even evolve
into absence status epilepticus [6, 16, 25]. The lack of tonic
seizures has been classically considered a major feature of
this syndrome and allows for differentiation from Lennox-
Gastaut syndrome (LGS) [1, 6, 25].
4.2. Neurocognitive Regression. During the dormant stage,
neurocognitive development is clinically normal in approx-
imately two-thirds of cases [13, 25, 26]. A severe neu-
rocognitive regression occurs around 5-6 years of age in
most patients. Neurocognitive deterioration affects a wide
spectrum of developmental and neurocognitive milestones
in varying but often severe degrees. Regression domains
include language, behavior, learning, memory, attention,
social interactions, motor skills, and global intelligence [2, 3,
6, 8, 15, 17, 25, 27–30].
5. Electroencephalographic Features
During wakefulness, the EEG shows focal/multifocal spikes
that increase in frequency during the acute stage. The hall-
mark EEG feature of CSWS is ESES. ESES is characterized
by (1) marked potentiation of epileptiform discharges during
non-REM sleep, leading to (2) a (near)-continuous, bilateral,
or occasionally lateralized slow spikes and waves, (3) and
these spikes and waves occur “during a significant propor-
tion” of the non-REM sleep with a threshold ranging from
25% to 85% [1, 6, 15, 19–21, 25, 27, 31–35].
5.1. Evolution of ESES over Time. Abnormal EEG findings
are found during the prodromal period or even the dormant
stage. Findings always include potentiation of spiking during
non-REM sleep. During the acute stage, interictal epilepti-
form activity becomes much more frequent and severe with
more widespread spikes of higher amplitude associated with
amoreabnormalbackground.Duringsleep,theEEGpattern
presents as ESES [4]. ESES typically appears about 4–8 years
of age and typically remits around 8-9 years of age [8, 17, 19,
35]. The age of detection of the ESES pattern on EEG varies
widelyindifferentstudiesandlikelyreflectsthevariedcriteria
of ESES used as well as the variations of time intervals in
which EEGs are performed.
5.2. Cut-Off Value. The initial definitions of ESES proposed
thatnolessthan85%ofthetotaldurationofslowsleepshould
beoccupiedbyslowspike-waves[6,34].Thiscut-offvaluehas
beenfollowedbyseveralauthors[6–8,15,17,21,35–39],while
other authors used lower cut-off percentages [19, 20, 40, 41].
The International League Against Epilepsy does not refer to
any particular threshold and only requires that spike-waves
be “continuous” and “diffuse” [1] leading to heterogeneous
and variable use of cut-off values by the professionals caring
for these children [9].
5.3. Quantification of Epileptiform Activity. The classic mea-
sureforthequantificationofepileptiformactivityisthespike-
wave index, expressed as the percentage of sleep occupied
by spike-waves. While this percentage has been widely used,Epilepsy Research and Treatment 3
(a) (b)
Figure1:Differentvaluesinthequantificationoftheepileptiformactivityresultwhenusingdifferentmethodsofquantification.Epileptiform
activity appears much more frequently in (b) than in (a). Both tracings have a 100% of epileptiform activity if the reader quantifies the
epileptiformactivityusingspikepercentage,thatis,countingthepercentageof1-secondbinsoccupiedbyspike-waves.However,ifthereader
quantifies the epileptiform activity using spike frequency, that is, the total number of individual spike-waves per unit of time (per 10 seconds
in this page, per 100 seconds in a longer tracing), epileptiform activity is almost double in (b) than in (a). Note that the tracings have different
voltage gains.
the exact method for calculating this value is often not
specified [6, 7, 15, 17, 19, 21, 26, 35, 40]. A reproducible way
to quantify epileptiform activity is to quantify the percentage
of 1-second bins with at least one spike-wave in them,
termedspike-wavepercentage[24,36].Anotherreproducible
method consists in counting the total number of spikes
per unit of time, termed spike frequency [24]. A formal
comparison between these two methods showed that spike
frequencycouldbetterdetectchangesinepileptiformactivity
in those patients with very active epileptiform discharges
(Figure 1)[24].Inaddition,spikefrequencylendsitselfbetter
for automated quantification [42]. There is also no formal
consensus on which portion of sleep is used for calculating
the epileptiform activity with different periods of the night
used by different authors [6, 19, 24, 35, 36, 43] and in clinical
practice[9].Regarding lateralizedepileptiformactivity,there
is insufficient evidence to support that unilateral or focal
discharges should be quantified differently than symmetric
and bilateral discharges [20, 26, 39, 44].
6. Evolution over Time
CSWS evolves over time, and this evolution manifests in
all three cardinal manifestations, including clinical seizures,
EEGabnormalities,andneurocognitiveregression.Wethere-
fore describe the evolution of this clinical presentation in
these three categories.
6.1.Seizures. Seizuresalmostalwaysdisappearwithage,even
in patients with a static or progressive encephalopathy [2, 3,
6, 25, 27, 29, 41, 45, 46]. The age of seizure freedom peaks
around 6–9 years of age although data on this clinical event
a r es c a r c e ,a n dt h er a n g ei sw i d e[ 27, 29].
6.2. Electroencephalogram Features. ESES progressively re-
solves with interictal epileptiform discharges during sleep
substituted by a progressive return of the physiologic
graphoelements and patterns of sleep. Typically, the reso-
lution of the ESES pattern occurs around 8-9 years of age,
in parallel with the timing of seizure freedom. However,
ESES can persist and be very active for a period after seizure
freedom [3, 24, 25, 29].
6.3.NeurocognitiveFeatures. Theinitialregressionultimately
leads to a plateau in development. Some patients present with
moderate improvements after seizure freedom. However,
most patients remain severely impaired [2, 3, 6, 47]. The
impact of interictal spikes on neurocognitive features is a
matter of debate, and it is not clear whether an increased
amount of epileptiform activity is associated with a worse
cognitive outcome [4, 48, 49].
7. Etiology and Pathophysiology
The exact cause of CSWS is unknown, but there are two
factors that have been implicated. First, an association of
CSWS with early developmentallesions of the brain has been
shown. Second, an increasing number of genetic associations
of unclear significance have also been described.
7.1. Early Developmental Lesions. Several case reports and
small series described the association between patients with
the ESES EEG pattern and early developmental lesions, such
as malformations of cortical development [45], or vascular
insults [50–52]. Larger series also support this association.
In a study of 32 patients with prenatal or perinatal thalamic
lesions, sleep potentiation of epileptiform activity occurred
in 29 cases (90.6%) [27]. In two large series of patients with
ESES, 33 out of 67 patients (49.3%) and 18 out of 44 (40.9%)
patients had an early developmental lesion [20, 53]. While
these lesions may not be specific for ESES, but for epilepsy
in general, a recent series compared 100 patients with ESES
and 47 patients with epilepsy without ESES. Patients with
ESES had a higher frequency of early developmental lesions
(48% versus 19.2%; P = 0.002) and a higher frequency of
thalamic lesions (14% versus 2.1%; P = 0.037). These findings
areconsistentwithotherseriessuggestingthatapproximately
40–50% of patients with ESES had an early developmental
insult [20, 53, 54], with a majority having perinatal lesions
of vascular etiology [20, 53, 54]. Interestingly, some authors
reportthatcertaincorticalmalformationsmayalsoberelated4 Epilepsy Research and Treatment
(a) (b)
Figure 2: Early vascular lesions in patients with CSWS. Axial view T2 weighted in (a), coronal view T2 weighted in (b). Extensive cystic
encephalomalacia affecting the left hemisphere in the distribution of the left middle cerebral artery consistent with a left middle cerebral
artery infarct.
Table 1: Genetic factors that have been described in association with CSWS.
Study Type of study Association
Beaumanoir et al.,
1995 [104] Case report CSWS in two monozygotic twins
Praline et al., 2006
[105] Case report Two siblings with ESES and different clinical presentations
Verhoeven et al.,
2012 [106] Case report One patient with CSWS and dysmorphic features carried a de
novo 8q12.3q13.2 microdeletion
Godfraind et al.,
2008 [107] Case report
One patient with CSWS carried a G392R mutation in
neuroserpin of probable pathogenic significance (the mutation
led to a progressive neurodegenerative disease and CSWS)
Nakayama et al.,
2012 [108] Case series (2 patients with CSWS) Two patients with CSWS and dysmorphic features carried an
unbalanced translocation between 8p and 9p
Broli et al., 2011
and Giorda et al.,
2009 [109, 110]
Case series (2400 subjects with isolated or
syndromic intellectual disability) Five patients with CSWS carried a Xp11.22-p11.23 duplication
Kevelam et al., 2012
[40]
Case series (13 children with ESES and
different clinical presentations)
Two patients with CSWS carried copy number variations in
CHRNA7 and PCYT1B genes of probable pathogenic
significance
Mefford et al., 2011
[111]
Case series (315 patients with different
epileptic encephalopathies, 29 had CSWS
or Landau-Kleffner syndrome)
One patient with CSWS carried a copy number variant in the
DOK5 gene of uncertain pathogenic significance
Reutlinger et al.,
2010 [112]
Case series (3 patients with ESES and
different clinical presentations)
Three patients with ESES and different clinical presentations
and dysmorphic features carried a deletion in 16p13.2p13.13
Atkins and
Nikanorova, 2011
[66]
Case series (20 patients with ESES and
different clinical presentations)
One patient with ESES (no further details on clinical
presentation) carried a partial trisomy 13/21
Legend: CSWS: continuous spikes and waves during sleep. ESES: electrical status epilepticus in sleep.
toearlyvascularinsults[55].Inparticular,earlydevelopmen-
tal lesions that involve the thalamus are strongly associated
with CSWS (Figure 2)[ 54].
7.2. Genetic Factors. Familialantecedentsofseizures(includ-
ing febrile seizures) are found in around 10–15% of patients
withCSWS[6,25].Althoughgeneticpredispositionseemsto
playaminorroleinCSWS,agrowingnumberofcasereports
and small series describe associations with copy number
variations and different mutations in several chromosomes
(Table 1). The etiological role of these genetic factors in
CSWS is largely undefined to date. It is likely that these
genetic variants are associated not with CSWS per se,b u t
with different neurological conditions that result in the final
common pathway of CSWS. A similar theory is suggested for
hypsarrhythmia in West syndrome.
7.3. Pathophysiology. Animal models are providing insights
into the basic pathophysiology of sleep-potentiated spikingEpilepsy Research and Treatment 5
[56]. Cortical lesions have been found to weaken the neuro-
transmissionbetweencorticothalamicneuronsandtheretic-
ular nucleus of the thalamus without weakening the circuit
between corticothalamic and thalamocortical neurons [57–
59].Therefore,reticularneuronsdonothavethenormalloop
interaction with the corticothalamic neurons that provides a
feed-forward inhibition to thalamocortical neurons [57]. In
contrast, a pathological loop with thalamocortical neurons is
created which promotes a robust oscillatory network in the
cortico-thalamo-cortical loop [57–59]. Breaking this patho-
logical loop by selective inhibition of the thalamocortical
neurons is a promising approach that has been found to
work in an animal model [59]. The deficiency of the GluA4
AMPAreceptorinaGria4
−/− mousemodelsimilarlyweakens
t h en o r m a lo u t p u to ft h er e t i c u l a rn e u r o n sl e a d i n gt ot h e
developmentofspike-wavedischarges[57].Itcanbehypoth-
esized that lesions in the reticular nucleus of the thalamus
may also lead to a potentiation of oscillatory discharges
in the cortico-thalamo-cortical network. Supporting this
hypothesis,markedsleeppotentiationofepileptiformactivity
has been found in patients with early developmental lesions
affecting the thalamus [27, 54]. The only study that evaluated
the specific thalamic areas that were injured showed that the
reticular nucleus was the most frequently affected structure
and it was involved in 91% of the cases [27].
8. Management
8.1. To Treat or Not to Treat Epileptiform Activity. The rela-
tionship of epileptiform activity in the EEG with neuropsy-
c h o l o g i c a lf u n c t i o ni sam a t t e ro fd e b a t e .N e a r - c o n t i n u o u s
epileptiform discharges are considered to be related to neu-
rocognitive regression in CSWS [6, 48, 49, 60]. Many studies
demonstrate that epileptiform activity is deleterious for
learningandmemoryundercertainexperimentalconditions
[48,49,60–65],indirectlysupportingtheoptionoftreatment.
A recent study associated epileptiform activity during ESES
with activation in the thalamocortical network and deactiva-
tion in the default mode network [38]. Since these networks
seem prominent in neuropsychological processes and con-
solidation of memory traces during sleep, it is possible that
epilepticspikesmaycontributetoregressioninCSWS.Onthe
o t h e rh a n d ,t h ei m p a c to fi n t e r i c t a le p i l e p t i f o r ma c t i v i t yo n
c o g n i t i v ef u n c t i o nm a yn o tb es e v e r ee n o u g ht os e r v ea st h e
sole explanation for the degree of neurocognitive regression
[48, 65]. Many studies suggest that long-term neurocognitive
function may significantly improve if epileptiform activity
in the EEG can be reduced with antiepileptic drugs [3, 6, 7,
17, 19, 49], but this effect remains to be proven. Therefore,
whethertotreatepileptiformactivitywithoutadirectclinical
correlate and, especially, to what extent to treat EEG findings
i su n c l e a r .A sar u l eo ft h u m b ,w ea l w a y st r e a tt h ep a t i e n t
while considering the clinical presentation as a whole, not
solely the EEG or other isolated laboratory values.
8.2.M odifica tionoftheN a tur alCourseoftheDiseasebyT r ea t-
ment. Treatment goals of CSWS include not only improved
seizure control, but also a reduction in EEG abnormalities
and potentially improvement of neurocognitive function or
at least prevention of further regression. There is evidence
i nt h el i t e r a t u r es u p p o r t i n gab e n e fi c i a le ff e c to ft r e a t m e n t
o ns e i z u r ef r e q u e n c ya n ds e v e r i t y[ 7, 19, 26, 36, 66–70]a n d
epileptiform activity [19, 21, 71, 72]. Several studies suggest
that long-term neurocognitive function can significantly
improve once epileptiform discharges are reduced, and this
effect has been related to treatment with antiepileptic drugs
[3, 6, 7, 17, 19, 73–77]. However, to date, there is no scientific
evidence for or against treatment of interictal spikes.
8.3. Antiepileptic Drugs. The most common antiepileptic
drugs used for CSWS include valproate, ethosuximide, and
levetiracetam [78]. In a series of 15 patients with CSWS
treated with high-dose valproate alone or with valproate
and ethosuximide, 10 cases (67%) responded with long-
term control of their epilepsy and partial recovery of cog-
nitive function [19]. In a separate study, the combination
of valproate and ethosuximide was effective in 2 additional
patients [7]. In contrast, other series did not report similar
improvements after treatment with comparable medication
regimes.Valproatewasreportedasnoteffectivein28patients
[26]; valproate and benzodiazepines did not achieve any
improvement in 7 patients and were associated with adverse
behavioral reactions in 3 children [30], and several case
r e p o r t sd e s c r i b en os i g n i fi c a n ti m p r o v e m e n tw i t hv a l p r o a t e
[67,68,79].Ethosuximidewasalsofoundtolackefficacyin7
patients with CSWS [26] and to exert only a modest effect in
3[ 67]. The efficacy of levetiracetam is supported by several
case reports in the literature [26, 36, 66–68, 70]. The only
placebo-controlled double-blind crossover study in patients
withESESshowedthattreatmentwithlevetiracetamreduced
epileptiform activity (from a spike index of 56 to 37) in a
series of 18 patients, although 3 other patients discontinued
treatment because of negative cognitive side effects [80].
Other drugs that have been reported as effective in small
series include sulthiame [26, 81] and lamotrigine [45, 82].
Phenytoin, phenobarbital, and, especially, carbamazepine
and oxcarbazepine are generally avoided because they have
beenassociatedwithexacerbationsofepileptiformdischarges
in patients with ESES [82–85].
8.4.High-DoseBenzodiazepines. Benzodiazepineshavedem-
onstrated efficacy in reducing epileptiform activity in the
short term. Transitory resolution of the ESES pattern was
observed after the administration of clonazepam [19, 21].
Diazepam has a shorter half-life than clonazepam, which can
be advantageous in a condition such as CSWS where more
severe epileptiform activity occurs during the night. In a
series of 4 patients with CSWS refractory to valproate and
ethosuximide, a short cycle of high-dose oral or intrarectal
diazepam (0.5–1mg/Kg per day for 6-7 days) was effective in
the short term in two patients [19] .I nas e r i e so f1 5p a t i e n t s
with CSWS, all patients responded to the treatment with
high-dose rectal diazepam [86]. High-dose oral diazepam
(0.75–1mg/Kg/day for 3 weeks) was also efficacious in 3 out
of 8 (37.5%) patients, but the response was temporary [26].
In 29 patients with ESES and different clinical presentations,6 Epilepsy Research and Treatment
the mean epileptiform activity decreased from 77% to 41%
after a nocturnal administration of 1mg/Kg of oral diazepam
[72]. This reduction in epileptiform activity persisted for
somemonths[87],butwhetherthisreductioninepileptiform
activity is accompanied by a sustained improvement in
clinical features remains to be proven. Other series show that
9 out of 10 patients did not respond to valproate and benzo-
diazepines, and 3 patients experienced an adverse behavioral
reaction [30]. Adverse effects of high-dose diazepam treat-
ment are generally considered mild and self-limited [72, 86],
but severe behavioral disinhibition and even the need for
discontinuation have also been described in few children
[3, 87].
8.5. Immune Modulation Therapy. Corticosteroids and intra-
venous immunoglobulins have shown improvement in
selected cases and, in some cases, lead to complete resolution
o fC S W S .O n c eC S W Si sr e c o g n i z e d ,u s u a l l yd u r i n gt h e
acute phase, corticosteroid treatment should be considered.
In a series of 44 children with a pattern of ESES and
clinicalpresentationsofvariableseverity,prolongedcorticos-
teroidtreatment(hydrocortisone5mg/kg/dayduringthefirst
month, 4mg/kg/day during the second month, 3mg/kg/day
during the third month, and 2mg/kg/day during the next 9
months, followed by slow withdrawal for a total treatment
duration of 21 months) led to reductions of seizures or
neuropsychological improvement in 34/44 (77.3%) cases,
with 34 achieving complete control of seizures and nor-
malization of EEG abnormalities in 21 patients. The long-
term remission rate was 45% [53]. However, the inclusion
of milder clinical presentations could make these results
d i ffi c u l tt oc o m p a r et oo t h e rs e r i e sw h e r ea l lo rm o s tp a t i e n t s
had clear CSWS [53]. In another series, a positive response
todifferentcorticosteroids(prednisone,methylprednisolone,
or adrenocorticotrophic hormone) was observed in 11 out
of 17 patients with CSWS [26]. The intramuscular admin-
istration of 0.001–0.04mg/kg/day of adrenocorticotrophic
hormone was reported to be effective in 1 out of 4 patients
[19]. The side effects of corticosteroid treatments usually
limit its long-term use. Only a handful of patients treated
with intravenous immunoglobulins have been reported in
the literature. Intravenous immunoglobulin treatment was
associated with improvements in 3 out of 9 patients with
CSWS [26]. In another series, the neurocognitive function
of 1 out of 3 patients with CSWS improved following the
administration of intravenous immunoglobulins [88]. How-
ever, there is probably a publication bias of positive results,
and the high cost and risk of complications associated with
immunoglobulins make their role in the treatment of CSWS
unclear.
8.6.SurgicalTreatment. Althoughclassicallyepilepsysurgery
was performed on patients with focal discharges, it has also
been successfully applied to select patients with general-
ized discharges [89, 90]. Some patients with CSWS may
also benefit from surgical treatment. Surgical interventions
include multiple subpial transections (MSTs), focal resective
surgeryoftheepileptogeniczone,hemispherectomyandcor-
pus callosotomy. MST consists of multiple small superficial
parallel cuts in the cortex that theoretically severs only the
local corticocortical connections in an attempt to disrupt
local epileptic circuitry without altering the vertical neural
c o l u m n sa n dt h e i rf u n c t i o n .I th a sb e e nr e p o r t e dt ol e a d
to recovery of age-appropriate speech in 7 patients out of
a series of 14 patients with Landau-Kleffner syndrome [89],
whereas a less dramatic language improvement was found in
other series [91, 92]. Two patients with CSWS secondary to
neonatal stroke markedly improved after hemispherectomy
[93]. In another study, two patients with CSWS secondary to
early developmental lesions in the thalamus became seizure-
free after a hemispherectomy in one and after an extensive
corticectomy around a large porencephalic cyst in the other
[27]. A study evaluated epilepsy surgery in 13 patients
with CSWS secondary to different early developmental
lesionswhounderwentvarioussurgicalproceduresincluding
anterior callosotomy (6 patients), complete callosotomy (3
patients), hemispherectomy (2 patients), and lobar resection
(2 patients). Subjects achieved an overall improvement in
seizure control and EEG features in most patients [8].
Improvements may be related to the type of surgery
performed.Thecognitivedeteriorationmaybehaltedinmost
patients; however, while there was some cognitive recovery,
patients did not return to baseline. In a series of 8 patients
with CSWS secondary to perinatal infarction (7 patients)
and a malformation of cortical development (1 patient), 6
patients underwent a hemispherectomy, and 2 underwent
focalresection.Resultsincludeddisappearanceofthepattern
of ESES (all 8 patients), seizure freedom (6 patients), marked
improvement in seizure control (2 patients), and an overall
improvementincognitivefunction(in3outof5patientswith
neuropsychological evaluation) [15]. Patients with CSWS
should undergo epilepsy surgery only after a careful evalu-
ation of potential benefits and risks in the individual patient.
A tendency toward neurocognitive improvement was found
in 3 out of 5 patients with CSWS after epilepsy surgery [15].
However, data on the long-term neurocognitive outcome of
surgically managed CSWS patients are not available.
8.7. General Suggestions for Managing Patients with CSWS
(Figure 3). Current literature does not permit the develop-
ment of an evidence-based management approach to CSWS.
Most of the drugs used for CSWS are selected based on
individual experience, case reports, or small case series that
claim efficacy for a specific drug. Responses to treatment in
uncontrolledcasereportsorcaseseriesshouldbeinterpreted
withcautionasanytreatmentforadisorderwithafluctuating
natural course tends to be initiated at the peak of severity,
so that some improvement can be attributed to the natural
fluctuations of the disease. In addition, other series report
a lack of efficacy for commonly used treatment options for
CSWS. There is no evidence on the efficacy of the ketogenic
diet in patients with CSWS. Here, we provide a practical
treatment approach based on case series in the literature
(Figure 3).Inpractice,mostpatientswithCSWSwerealreadyEpilepsy Research and Treatment 7
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Figure 3: Options for the management of patients with CSWS. Options for chronic management are high-dose benzodiazepines, standard
antiepileptic drugs in different combinations, and corticosteroids and immune-modulating agents. These options are considered as first
choices by different authors, although standard antiepileptic drugs are generally used before the recognition of CSWS. Epilepsy surgery
is reserved for few selected refractory cases. Legend: ACTH: adrenocorticotrophic hormone. CLB: clobazam. DZP: diazepam. ETX:
ethosuximide. LEV: levetiracetam. LTG: lamotrigine. LZP: lorazepam. MPRD: methylprednisolone. MST: multiple subpial transection. SUL:
sulthiame. VPA: valproate.
on some standard antiepileptic drug (valproate, levetirac-
etam, or similar) when their seizures first began and before
their condition was recognized as CSWS. Once in the acute
phase,standardantiepilepticdrugs,corticosteroids,andben-
zodiazepines can be considered as first choices depending on
theparticularpatientandthefamiliarityofthephysicianwith
these drugs. Several groups have reported the usefulness of
benzodiazepines[19,26,72,86],andafrequentprotocolused
atourinstitutionsisnocturnalDiazepam1mg/Kgduringthe
firstnightfollowedby0.5mg/Kgeveryfollowingnightfor1 –3
months [87]. For the chronic management of CSWS and par-
ticularlyforseizurecontrolstandardantiepilepticdrugssuch
as valproate, ethosuximide, levetiracetam, sulthiame, and
lamotrigine are frequently used. Polytherapy is often needed.
Medication selection should be guided by presenting seizure
types [7, 19, 26, 30, 36, 45, 66–68, 70, 78–82]. Other options
includetreatmentwithcorticosteroids,adrenocorticotrophic
hormone, or intravenous immunoglobulin [19, 26, 53, 88].
Epilepsy surgery should be considered, especially in patients
w i t ha ne a r l yu n i l a t e r a ld e v e l o p m e n t a ll e s i o n ,e v e nw h e nt h e
epileptiform activity on EEG is generalized [8, 15, 27, 89–93].
For the acute control of very active nighttime epileptiform
discharges, high-dose benzodiazepines have been used over
ap e r i o do faf e wm o n t h s[ 19, 21, 26, 72, 86]. While adequate
control of seizures improves the quality of life of the patients
andshouldbepursued,itisunknownhowaggressivelyinter-
ictalepileptiformactivityinrelationshipwithneurocognitive
regression should be treated. Only prospective studies that
correlate the response to treatment of interictal epileptiform
activity with the improvement in neurocognitive function
will be able to answer that relevant question.
9. Related Conditions
ESES,theEEGpatternthatcharacterizesCSWS,canbefound
inotherelectroclinicalconditions.CSWSmightrepresentthe
most severe end of a continuum in which Landau-Kleffner
syndrome would be an intermediate condition and “benign”
f o c a le p i l e p s ys y n d r o m e so fc h i l d h o o dw o u l db ea tt h em o s t
benign end of the spectrum.
9.1. Landau-Kleffner Syndrome. It is an age-related epilep-
tic encephalopathy where regression occurs mainly in the
language spectrum and the EEG abnormalities are more
centered around the temporal-parietal regions [94]. Seizures
are not a prominent part of this syndrome, and they are
either infrequent or do not even occur in 20–30% of cases
[3, 74]. Contrary to CSWS, structural brain lesions in LKS
a r ea nex cep tio nt oth erule[94]. Most antiepilepticdrugsare
effective for seizure control in LKS [7, 18, 21]. Corticosteroids
have been reported to markedly improve the evolution of
the disease [18, 53, 77], and intravenous immunoglobulins
demonstrated promising results in very few cases, although
immunoglobulins are expensive and associated with poten-
tially serious side effects [88, 95–99]. Resective surgery is
n o ta no p t i o nb e c a u s et h ef o c u so fe p i l e p t i f o r ma c t i v i t y
frequentlyinvolveseloquentcortex,includinglanguageareas.
The technique of multiple subpial transections has led to8 Epilepsy Research and Treatment
variable results [91, 92, 100]. Similar to CSWS, seizures and
EEGabnormalitiesnormalizeovertime,butmostpatientsdo
not recover their baseline language status [76].
9.2. “Benign” Pediatric Focal Epileptic Syndromes. They
include“Benign”epilepsyofchildhoodwithcentral-temporal
spikes, Panayiotopoulos syndrome, and Gastaut-type late-
onset childhood occipital epilepsy. These syndromes share
features such as a strong genetic predisposition, age-related
appearance and disappearance of electroclinical manifes-
tations, and a relatively “benign” clinical course. As in
the previous syndromes, interictal epileptiform activity
may be disproportionately severe in comparison with the
seizure correlation. Neurocognitive dysfunction, if present,
is mild. The individual description of each particular syn-
drome is beyond the scope of this review and can be
found elsewhere [101, 102]. Because of their main features,
“benign” pediatric focal epileptic syndromes may be con-
sidered as part of the electroclinical spectrum of CSWS
[101, 102].
9.3. Seizure (or Spikes) Susceptibility Syndrome. CSWS,
Landau-Kleffner syndrome and “benign” pediatric focal
epilepsy syndromes share a series of common features: (1)
an electroclinical syndrome consisting of seizures, interic-
tal epileptiform activity, and neuropsychological deficits of
different severities, (2) an age-related evolution with onset
in early childhood and spontaneous improvement before
puberty,(3)interictalepileptiformactivitybecomesmarkedly
potentiated during non-REM sleep, (4) interictal epilepti-
formactivityisdisproportionatelysevereincomparisonwith
the seizure correlate, and (5) interictal epileptiform activity
frequently persists after seizure freedom. Overlap between
these clinical presentations has led to the hypothesis of a
common seizure susceptibility syndrome. In this syndrome,
the different electroclinical presentations reflect different
severities of a common underlying pathophysiology, similar
to what happens with the different clinical presentations of
hypsarrhythmia. A genetic or acquired disruption of the
neural networks early in development would create hyperex-
citableneuralnetworks[57,58]that,dependingonitsseverity
and localization, could manifest as different electroclinical
presentations in the spectrum [27, 54, 56, 101, 103].
10. Conclusions
CSWS is an age-related epileptic encephalopathy that repre-
sents the most severe end of the childhood seizure suscep-
tibility syndrome. Its characterizing features are (1) seizures,
(2) interictal epileptiform activity that becomes prominent
during sleep leading to the electroencephalogram pattern
of ESES, and (3) neurocognitive regression. The etiology of
CSWS is unknown, but early developmental lesions play a
m a j o rr o l ei na r o u n dh a l fo ft h ec a s e s .Th en e u r o c o g n i t i v e
outcome is generally poor, and it is currently unknown
whethertreatmentcanmodifyit.High-dosebenzodiazepines
have been used successfully to decrease very active epilepti-
formdischarges.Polytherapywithcombinationsofvalproate,
ethosuximide, levetiracetam, sulthiame or lamotrigine, and
corticosteroids is frequently used. Epilepsy surgery can be
consideredinafewveryselectednumberofpatients.Abetter
understanding of the response to treatment, the electro-
clinical spectrum, and the underlying pathophysiology may
allowforthedevelopmentofanevidence-basedmanagement
approach in the future.
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